List view / Grid view


Precision medicine for complex chronic diseases: how near are we?

28 April 2022 | By , ,

Targeting medicines against the genetic and molecular drivers of lung, breast and other tumours has helped transform cancer care for many patients, yet precision medicine for complex chronic diseases has lagged behind. Maria Orr, Adam Platt and Ben Challis, from BioPharmaceuticals R&D at AstraZeneca, explain why this is changing for…

The future of CMC for novel therapies

22 April 2022 | By

Novel and advanced therapies have come on in leaps and bounds over the past decade. Some cell and gene therapies have already reached the approvals stage, while others have now entered the later development stages. As a result, manufacturing process consistency, GMP standards and more must now meet more formal…

Engaging the innate immune system to fight cancer effectively

22 April 2022 | By

Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…

Guide to Testing

20 April 2022 | By

Welcome to European Pharmaceutical Review’s Guide to Testing. In this edition, Oliver Großgart, Plant Safety Expert at TÜV SÜD Industrie Service GmbH, discusses the benefits of leveraging acoustic emission testing to identify faults in compressed air pressure vessels, and Associates of Cape Cod and SGS Health Science showcase their services,…

Drug Formulation In-Depth Focus 2022

19 April 2022 | By

Features in this in-depth focus highlight developments in the MRI contrast agent space, explore the development of precision medicine for chronic diseases and explain why immunotherapies should engage the innate immune system in the fight against cancer.